Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Foretinib (GSK1363089) 是多靶点酪氨酸激酶抑制剂,能够抑制 Met (IC50:0.4 nM) 和 KDR (IC50:0.9 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 342 | 现货 | ||
2 mg | ¥ 488 | 现货 | ||
5 mg | ¥ 822 | 现货 | ||
10 mg | ¥ 1,370 | 现货 | ||
25 mg | ¥ 2,330 | 现货 | ||
50 mg | ¥ 3,490 | 现货 | ||
100 mg | ¥ 4,960 | 现货 | ||
500 mg | ¥ 10,600 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 996 | 现货 |
产品描述 | Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. |
靶点活性 | FLT4:2.8 nM (cell free), FLT3:3.6 nM (cell free), RON:3 nM (cell free), Tie2:1.1 nM (cell free), KDR:0.86 nM (cell free), MET:0.4 nM (cell free) |
体外活性 | Foretinib (EXEL-2880) inhibits HGF receptor family tyrosine kinases with IC50 values of 0.4 nmol/L for Met and 3 nmol/L for Ron. EXEL-2880 also inhibits KDR, Flt-1, and Flt-4 with IC50 values of 0.9, 6.8, and 2.8 nmol/L, respectively. EXEL-2880 is a potent inhibitor of cellular Met with IC50 values of 23 and 21 nmol/L, respectively, in PC-3 prostate cells and murine B16F10 melanoma cells [1]. In MKN-45, 1 μM of foretinib inhibited phosphorylation of MET and downstream signaling molecules. Further, 1 μM of foretinib inhibited phosphorylation of FGFR2 and downstream molecules, suggesting that foretinib targets FGFR2 in KATO-III. Foretinib inhibits phosphorylation of epidermal growth factor receptor (EGFR), HER3 and FGFR3 via MET inhibition in MKN-45, and EGFR, HER3 and MET via FGFR2 inhibition in KATO-III [2]. |
体内活性 | A single 100 mg/kg oral gavage dose of EXEL-2880 resulted in substantial inhibition of phosphorylation of B16F10 tumor Met, which persisted through 24 h. Once daily oral gavage administration of EXEL-2880 resulted in a dose-dependent reduction in tumor burden of 31% and 62%, respectively, for doses of 30 and 100 mg/kg. The lung surface tumor burden, calculated by multiplying the total nodule count by the average nodule diameter for each tumor, was reduced by 50% and 58% following treatment with 30 and 100 mg/kg EXEL-2880, respectively [1]. The daily oral administration of foretinib (30 mg/kg) significantly inhibited the growth of tumor in all three of the tumor xenografts starting after only seven days of administration, and lasting throughout the experiment. Moreover, TEN cell tumor xenografts completely vanished in all specimens after 14 days of foretinib treatment [3]. |
激酶实验 | Kinase inhibition was investigated using one of three assay formats: [33P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology. Further assay details are provided in Supplementary Section. IC50 values were calculated by nonlinear regression analysis using XLFit [1]. |
细胞实验 | PC-3 and B16F10 cells were seeded in 24-well plates overnight. The cells were then washed and incubated with serum-free medium for 3 h followed by a 1 h incubation with EXEL-2880 before addition of HGF (100 ng/mL) for 10 min. Met phosphorylation status was determined by ELISA analysis (Supplementary Data). For determination of VEGF-stimulated extracellular signal-regulated kinase phosphorylation, human umbilical vein endothelial cells were seeded in 96-well plates and incubated for 24 h and then serum-starved for another 24 h. A serial dilution of EXEL-2880 was added for 1 h before a 5 min stimulation with VEGF (20 ng/mL). Medium was removed, and the cells were fixed with Cytofix and then treated with 0.6% H2O2. Plates were blocked with 10% FBS and incubated with a mouse monoclonal anti-phosphorylated extracellular signal-regulated kinase p44/42 antibody (E10) followed by incubation with goat anti-mouse IgG-horseradish peroxidase and chemiluminescent detection. IC50 values were calculated based on triplicate experiments [1]. |
动物实验 | B16F10 tumor cells (2 × 10^5) were implanted via i.v. tail vein injection into mice on day 0. EXEL-2880 or vehicle administration was initiated 3 days after implantation for 10 days followed by assessment of lung tumor burden. Lungs were excised, weighed, and zinc-fixed for 24 h, and the number of nodules formed on all lobe surfaces was counted using a Zeiss stereoscope. Lung nodule diameters were morphometrically measured on digitally captured images. Inhibition of tumor burden as measured by lung wet weight was calculated as follows: % tumor growth inhibition = [(compound treated-naive / vehicle-naive) × 100]. The results for each treatment group (n = 10 animals) were averaged, and statistical t test analysis was done comparing each treatment group to the vehicle-treated control [1]. |
别名 | GSK089, EXEL-2880, GSK1363089, XL880 |
分子量 | 632.65 |
分子式 | C34H34F2N4O6 |
CAS No. | 849217-64-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 63.3 mg/mL (100 mM)
DMSO: 63.3 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.5807 mL | 7.9033 mL | 15.8065 mL | 39.5163 mL |
5 mM | 0.3161 mL | 1.5807 mL | 3.1613 mL | 7.9033 mL | |
10 mM | 0.1581 mL | 0.7903 mL | 1.5807 mL | 3.9516 mL | |
20 mM | 0.079 mL | 0.3952 mL | 0.7903 mL | 1.9758 mL | |
50 mM | 0.0316 mL | 0.1581 mL | 0.3161 mL | 0.7903 mL | |
100 mM | 0.0158 mL | 0.079 mL | 0.1581 mL | 0.3952 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Foretinib 849217-64-7 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Tie-2 c-Met/HGFR GSK-1363089 inhibit GSK-089 GSK089 XL-880 GSK 1363089 Inhibitor EXEL-2880 GSK 089 GSK1363089 EXEL 2880 XL880 Vascular endothelial growth factor receptor EXEL2880 XL 880 inhibitor